NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...
AbbVie (ABBV) announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a ...
Pharmaceutical Technology on MSN6d
AbbVie and Neomorph link on oncology/immunology glue degradersAbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.
Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback